E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Psychiatry and Psychology [F] - Mental Disorders [F03] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10039626 |
E.1.2 | Term | Schizophrenia |
E.1.2 | System Organ Class | 10037175 - Psychiatric disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The purpose of this study is to evaluate the outcome of medication discontinuation, the safety and effectiveness of re-initiating risperidone long acting injection (RLAI) in case of relapse (the return of a medical problem) of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) during the study observation period of 36 months. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Participants who completed 24 months RIS-PSY-301 study
- Surgically sterile female participants or practicing an effective method of birth control before entry and throughout the study; and must have shown a negative urine serum pregnancy test at baseline before study entry
- Participants who have signed informed consent document |
|
E.4 | Principal exclusion criteria |
- Participants requiring treatment with mood stabilizers or antidepressants at study entry
- Participants with evidence of alcohol or drug abuse or dependence (except for nicotine and caffeine dependence) according to Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria diagnosed in the last month before entry
- Participants with a history of severe drug allergy, drug hypersensitivity, or neuroleptic malignant (cancerous) syndrome
- Participants with known hypersensitivity to risperidone
- Participants with acute risk of suicide at study entry or a history of suicidal attempt(s) |
|
E.5 End points |
E.5.1 | Primary end point(s) |
- Time to Relapse After Discontinuation of Risperidone Long-Acting Injection (RLAI) in First-Episode Participants Successfully Treated for 24 Months With RLAI in Previous Study (RIS-PSY-301) (Period 1)
- Percentage of Participants who Relapsed After Discontinuation of RLAI (Period 1)
- Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score After Re-Initiation of RLAI, at Month 24 or EW (Period 2)
- Time to Treatment Response After Re-Initiation of RLAI (Period 2) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
- Month 36 or early withdrawal (EW)
- Month 36 or EW
- Baseline and Month 24 or EW
- Month 24 or EW
|
|
E.5.2 | Secondary end point(s) |
- Change From Baseline in PANSS Total Score and Subscales of PANSS at Month 36 or EW (Period 1)
- Change From Baseline in PANSS Total Score and Subscales of PANSS at Month 24 or EW (Period 2)
- Change From Baseline in Marder PANSS Subscales Score at Month 36 or EW (Period 1)
- Change From Baseline in Marder PANSS Subscales Score at Month 24 or EW (Period 2)
- Number of Participants With Disease Remission Based on PANSS (Period 1)
- Number of Participants With Disease Remission Based on PANSS (Period 2)
- Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score at Month 36 or EW (Period 1)
- Clinical Global Impression of Change (CGI-C) Score at Month 36 or EW (Period 1)
- Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score at Month 24 or EW (Period 2)
- Clinical Global Impression of Change (CGI-C) Score in Period 2 at Month 24 or EW (Period 2)
- Change From Baseline in Calgary Depression Scale Score for Schizophrenia (CDSS) at Month 36 or EW (Period 1)
- Change From Baseline in Calgary Depression Scale Score for Schizophrenia (CDSS) at Month 24 or EW (Period 2)
- Change From Baseline in Social and Occupational Functioning Assessment Scale (SOFAS) Score at Month 36 or EW (Period 1)
- Change From Baseline in Social and Occupational Functioning Assessment Scale (SOFAS) Score at Month 24 or EW (Period 2)
- Change From Baseline in Patient Global Impression-Severity (PGI-S) Score at Month 36 or EW (Period 1)
- Patient Global Impression-Change (PGI-C) Score at Month 36 or EW (Period 1)
- Change From Baseline in Patient Global Impression-Severity (PGI-S) Score at Month 24 or EW (Period 2)
- Patient Global Impression-Change (PGI-C) Score at Month 24 or EW (Period 2)
- Change From Baseline in 12-Item Short-Form (SF-12) Score - Quality of Life Survey at Month 36 or EW (Period 1)
- Change From Baseline in 12-Item Short-Form (SF-12) Score - Quality of Life Survey at Month 24 or EW (Period 2) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- Baseline and Month 36 or EW
- Baseline and Month 24 or EW
- Baseline and Month 36 or EW
- Baseline and Month 24 or EW
- Month 36 or EW
- Month 24 or EW
- Baseline and Month 36 or EW
- Month 36 or EW
- Baseline and Month 24 or EW
- Month 24 or EW
- Baseline and Month 36 or EW
- Baseline and Month 24 or EW
- Baseline and Month 36 or EW
- Baseline and Month 24 or EW
- Baseline and Month 36 or EW
- Month 36 or EW
- Baseline and Month 24 or EW
- Month 24 or EW
- Baseline and Month 36 or EW
- Baseline and Month 24 or EW |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
Will this trial be conducted at a single site globally?
| Yes |
E.8.4 | Will this trial be conducted at multiple sites globally? | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 4 |